Divestment
Syntaxin
Syntaxin developed engineered botulinum toxin biologics for pain, bladder disorders, and endocrine diseases.
Key Facts
- Sector
Life Sciences
- Country
United Kingdom
- Fund
LSP 3
- Entry
2007
- Exit
2013
Divestment
Syntaxin developed engineered botulinum toxin biologics for pain, bladder disorders, and endocrine diseases.
Life Sciences
United Kingdom
LSP 3
2007
2013
